Sugi Predict

Sugi Predict / Compounds / SCHEMBL598704

SCHEMBL598704

SCHEMBL598704

CC(C)(C)OC(=O)N1C(=O)CC[C@H]1Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KLK7 P49862 6/20 0.45
▸ KLK5 Q9Y337 5/20 0.42
▸ USP30 Q70CQ3 3/20 0.42
▸ PRSS1 P07477 2/20 0.41
▸ PRSS2 P07478 2/20 0.41
▸ PRSS3 P35030 2/20 0.41
▸ HCRTR1 O43613 1/20 0.39
▸ HCRTR2 O43614 1/20 0.39
▸ GPR119 Q8TDV5 3/20 0.39
▸ NR1H2 P55055 2/20 0.39
▸ NR1H3 Q13133 2/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ DPP4 P27487 1/20 0.38
▸ STS P08842 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL598705 1.00 KLK7 (0.45) KLK7KLK5USP30PRSS1PRSS2
SCHEMBL19419776 0.93 KLK7 (0.51) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL15383781 0.93 KLK7 (0.51) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL3728443 0.93 KLK7 (0.51) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL19191376 0.89 DPP4 (0.44) KLK7USP30GPR119NR1H2NR1H3
SCHEMBL18626434 0.89 NR1H2 (0.41) KLK7USP30HCRTR1HCRTR2GPR119
SCHEMBL11994282 0.88 GRM2 (0.40) KLK7USP30GPR119NR1H2NR1H3
SCHEMBL14932460 0.88 GRM2 (0.41) KLK7USP30NR1H2NR1H3STS
SCHEMBL14902420 0.87 GRM2 (0.40) KLK7KLK5PRSS1PRSS2PRSS3
SCHEMBL6969013 0.87 KLK7 (0.48) KLK7KLK5PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851443-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-12-26 — — US disclosed
US-20230285340-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-09-14 — — US disclosed
US-11547687-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-01-10 — — US disclosed
US-20220298173-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-09-22 — — US disclosed
US-11261197-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-03-01 — — US disclosed
US-11174219-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-11-16 — — US disclosed
US-20210155576-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-05-27 — — US disclosed
US-20210079017-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-18 — — US disclosed
US-20210079017-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-18 — — US disclosed
US-20210059966-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-04 — — US disclosed
US-20110046397-A1 NEW PROCESSES NOVARTIS PHARMACEUTICALS CORPORATION 2011-02-24 — — US disclosed
EP-2245009-A2 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES Novartis AG (CH) 2010-11-03 — — EP disclosed
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS PHARMACEUTICALS CORPORATION 2010-05-06 — — US disclosed
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS PHARMACEUTICALS CORPORATION 2010-05-06 — — US disclosed
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS PHARMACEUTICALS CORPORATION 2010-05-06 — — US disclosed
EP-2121578-A2 NEW PROCESS Novartis AG (CH) 2009-11-25 — — EP disclosed
WO-2009090251-A2 NEW PROCESSES NOVARTIS AG (CH) 2009-07-23 — — WO disclosed
WO-2009090251-A2 NEW PROCESSES NOVARTIS AG (CH) 2009-07-23 — — WO disclosed
WO-2008083967-A2 PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID NOVARTIS AG (CH) 2008-07-17 — — WO disclosed
WO-2008083967-A2 PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID NOVARTIS AG (CH) 2008-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285340-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 241/4885KLK5 112/4885USP30 3480/4885
US-20110046397-A1 NEW PROCESSES MME, REN, AGTR1 KLK7 2766/4885KLK5 1892/4885USP30 830/4885
US-20100113801-A1 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid MME, REN, PAH KLK7 3403/4885KLK5 1873/4885USP30 793/4885
US-11174219-B2 Neprilysin inhibitors MME, REN, ACE KLK7 262/4885KLK5 245/4885USP30 1563/4885
US-11547687-B2 Neprilysin inhibitors MME, REN, ACE KLK7 241/4885KLK5 112/4885USP30 3480/4885
US-11261197-B2 Neprilysin inhibitors MME, REN, ACE KLK7 302/4885KLK5 152/4885USP30 2899/4885
US-20210155576-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 262/4885KLK5 245/4885USP30 1563/4885
US-20210079017-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 302/4885KLK5 152/4885USP30 2899/4885
US-20210059966-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 241/4885KLK5 112/4885USP30 3480/4885
US-20220298173-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK7 304/4885KLK5 145/4885USP30 2927/4885
US-11851443-B2 Neprilysin inhibitors MME, REN, ACE KLK7 302/4885KLK5 152/4885USP30 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.